Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/10/2025

Safe Use of Carafate with Prednisone

Clinical Applications and Dosage

  • The American Gastroenterological Association recommends prednisone as the standard corticosteroid for inducing remission in moderate-to-severe ulcerative colitis and Crohn's disease, typically dosed at 40-60 mg daily, with tapering over 4-6 weeks, according to the Journal of Clinical Oncology and Gut 1, 2, 3
  • For patients with radiation-induced rectal bleeding, sucralfate enemas are recommended as first-line therapy, with a dosage of 2g in 30-50 mL water, twice daily, as suggested by Gut 4, 5
  • The European Society for Medical Oncology guidelines suggest that sucralfate is not recommended for prevention of radiation-induced oral mucositis, but it may be used for mucosal protection in other inflammatory conditions, as stated in the Annals of Oncology 6
  • The National Institute of Health recommends monitoring for constipation, as it is the most common side effect of sucralfate, and administering quinolone antibiotics more than 2 hours before sucralfate due to potential chelation, as reported by MMWR Recommendations and Reports 9
  • The American College of Gastroenterology suggests that prednisone increases the risk of peptic ulcer disease, and proton pump inhibitors or H2-receptor antagonists are typically recommended for GI protection during corticosteroid therapy, according to the Journal of Clinical Oncology 1, 7, 8

Gastrointestinal Protection and Interactions

  • Sucralfate may provide additional gastroprotection in patients on prednisone by forming a protective barrier over inflamed mucosa and increasing local prostaglandin concentrations, as reported by the Journal of Clinical Oncology 1, 7, 8
  • Quinolone antibiotics should be administered more than 2 hours before sucralfate to avoid decreased absorption due to chelation, as recommended by MMWR Recommendations and Reports 9